Drug Profile
CORT 108297
Alternative Names: ADS-108297; CORT-108297Latest Information Update: 29 Nov 2022
Price :
$50
*
At a glance
- Originator Corcept Therapeutics
- Developer Corcept Therapeutics; Johns Hopkins University
- Class 3-ring heterocyclic compounds; Obesity therapies; Pyrazoles; Quinolines; Small molecules; Sulfones
- Mechanism of Action Glucocorticoid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Alzheimer's disease; Cognition disorders; Memory disorders; Post-traumatic stress disorders
- Discontinued Psychiatric disorders; Weight gain
Most Recent Events
- 29 Nov 2022 CORT108297 is still in phase II trials for Mild Cognitive impairment, Alzheimer disease, Memory impairment and Post-traumatic stress disorder in USA (NCT04601038) (Corcept therapeutics pipeline, November 2022)
- 31 Aug 2021 VA Office of Research and Development plans a phase IIa trial for Post-traumatic stress disorders (In adults, In the elderly) in USA (PO) in September 2021 (NCT04452500) (Corcept Therapeutics pipeline, August 2021)
- 23 Oct 2020 Phase-II clinical trials in Alzheimer's disease (In adults, In the elderly) in USA (PO) (NCT04601038)